157 results on '"Connolly, Caoilfhionn"'
Search Results
2. Idiopathic inflammatory myopathies: current insights and future frontiers
3. Myopathy in systemic sclerosis
4. Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease
5. Prevalence and Risk Factors of Postacute Sequelae of COVID-19 in Adults With Systemic Autoimmune Rheumatic Diseases.
6. Peeling and Plummeting
7. 249.8: SARS-coV-2 Antibody Response by mRNA Vaccine Platform in Incrementally Immunosuppressed Patients
8. Castleman disease patients report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccination
9. Three doses of COVID-19 mRNA vaccine induce class-switched antibody responses in inflammatory arthritis patients on immunomodulatory therapies
10. Antibody Kinetics after Three Doses of SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease
11. Clinical pearls and promising therapies in myositis
12. Periorbital Edema in Dermatomyositis
13. Durability of Antibody Response Six Months After Two-Dose SARS-CoV-2 mRNA Vaccination in Patients with Cirrhosis
14. Bullous periorbital oedema in anti-p155/140-positive dermatomyositis: a case series
15. Immunogenicity and Reactogenicity Following 2- and 3-Dose SARS-CoV-2 Vaccination in Persons With HIV
16. Low Omicron BA.4 and BA.5 neutralising activity and breakthrough COVID-19 following pre-exposure prophylaxis with tixagevimab plus cilgavimab in vaccinated patients with autoimmune disease
17. Intolerable Unilateral Hip Pain: Clues from the History
18. Effect of mycophenolate mofetil dose on antibody response following initial SARS-CoV-2 vaccination in patients with systemic sclerosis
19. Lipoprotein(a) in systemic lupus erythematosus is associated with history of proteinuria and reduced renal function
20. Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease
21. SARS-CoV-2 vaccination in the immunocompromised host
22. Safety and immunogenicity of fifth dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series
23. Factors associated with poor antibody response to third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases
24. Possible future avenues for myositis therapeutics: DM, IMNM and IBM
25. Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease
26. Safety of third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal disease
27. Comparison of SARS-CoV-2 Antibody Response After 2-Dose mRNA-1273 vs BNT162b2 Vaccines in Incrementally Immunosuppressed Patients
28. Humoral response following SARS-CoV-2 vaccination: not all immunosuppressants are created equal
29. Supplemental Material - Lipoprotein(a) in systemic lupus erythematosus is associated with history of proteinuria and reduced renal function
30. Antibody Response 3 Months After 2-Dose SARS-CoV-2 mRNA Vaccination in Patients With Inflammatory Bowel Disease
31. Attenuated response to fourth dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series
32. Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two‐Dose SARS – CoV ‐2 Messenger RNA Vaccination
33. Impact of methotrexate on first-dose COVID-19 mRNA vaccination
34. Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination
35. Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series
36. Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series
37. Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series
38. Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases
39. Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response” by Bonelli et al
40. High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases
41. Segmental arterial mediolysis: a rare cause of abdominal pain masquerading as vasculitis
42. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases
43. Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases
44. Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two‐Dose SARS–CoV‐2 Messenger RNA Vaccination.
45. Immune-Related Adverse Events: A Case-Based Approach
46. 066. HISTOLOGIC AND CLINICAL PROGRESSION OF ANCA-ASSOCIATED GLOMERULONEPHRITIS
47. Effects of Ischemic Preconditioning on Abdominal Aortic Aneurysm Repair: A Systematic Review and Meta-analysis
48. Anakinra for Recurrent Fevers in Systemic Lupus Erythematosus
49. Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series.
50. Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.